Antimicrobial Arrowg+ard Blue Advance Catheters®

Protect from pathogens on the CDC’s “Severe Threats” List

What's the threat?
The invisible risk
According to the CDC,
antibiotic resistance is one of
the greatest global public1
health challenges of our time.

Click here to read the 2019 CDC AR Threats Report

How are providers
responding?
Antimicrobial Stewardship
Programs
Hospital antimicrobial stewardship programs
are implementing systematic programs andpractices in order to limit the use ofantibiotics that could result in increasing
antibiotic resistance in dangerous bacteria.

What are yourchallenges?
Stopping the spreadof antibiotic resistantpathogens
Catheters help treat patients, but
can be pathways for germs(including antibiotic resistantbacteria) to enter the body.

Click here to read evidence-based practices from the2020 Joint Commission National Patient Safety Goals

How can Teleflex help?
With Arrowg+ard Blue®
Advance Catheters
Arrowg+ard Blue Advance Catheters are the 3rd
generation of chlorhexidine-based protective treatment
from Teleflex.

Arrowg+ard Blue Advance Catheters havebeen shown to provide at least 99.99%
reduction in catheter colonization by
gram-positive and gram-negative bacteria
2and fungi for at least 30 days.

99.99%Colonization
3Reduction

Where's the proof?
The power of blue
In a controlled benchtop study, antimicrobial

Six antibiotic
resistant pathogens vs.
Arrowg+ard Blue
Advance Protection

Arrowg+ard Blue Advance Catheters demonstrated a®

100% decrease in bioburden on the catheter surfaceof various CLABSI pathogens (6 of them antibiotic
3

resistant and on the CDC Serious Threats ), including:1• Carbapenem Resistant Enterobacter cloacae• Methicillin Resistant Staphylococcus epidermidis• Carbapenem Resistant Escherichia coli
• Carbapenem Resistant Klebsiella pneumoniae• Vancomycin Resistant Enterococcus faecalis

See page 9, Comparing Antimicrobial Effectiveness,for testing data.

100% decrease• Methicillin Resistant Staphylococcus aureus

In that same test, the Bard PICC and the®

AngioDynamics Bioflo PICC actually®

demonstrated an increase in bioburden in fiveout of six tested antibiotic resistant pathogens

3on the CDC Serious Threats List tested,1

including:

Increase in bioburden

Where's the proof?

• Methicillin Resistant Staphylococcus aureus• Carbapenem Resistant Enterobacter cloacae• Carbapenem Resistant Escherichia coli
• Carbapenem Resistant Klebsiella pneumoniae• Vancomycin Resistant Enterococcus faecalis

See page 9, Comparing Antimicrobial Effectiveness,for testing data.

Six Antibiotic resistantpathogens vs. Bard PICC andAngiodynamics Bioflo PICC

Using a protected Arrowg+ard Blue Advance Catheter canhelp you combat antibiotic resistant bacteria by:®

• Reducing catheter colonization from major CLABSI causing
pathogens including antibiotic resistant bacteria on• Protecting the catheter inside and out with antimicrobial
protection along the entire intra- and extraluminal fluid
pathway, including the extension lines

Click here to see video of the antimicrobial
Arrowg+ard Blue Advance Catheter in actionComparing Antimicrobial Effectiveness

3

Objective: To evaluate and compare the antimicrobial effectiveness of three different types of commerciallyavailable Peripherally Inserted Central Catheters (PICCs) against six antibiotic-resistant bacteria (superbugs).
Methodology: Equal segments were cut from three groups of PICCs: Chlorhexidine-based (Group A), Fluorine-based (Group B), anduntreated (Group C). The external surface of the cut segments was challenged with one of the six tested organisms for 24 hours. All sixorganisms were tested on each of the three groups. The concentration of the challenge inoculum for each organism was at 1.5 x105 Colony
Forming Units per Milliliter (CFU/mL). Adherent microorganisms were recovered by sonication in Dey-Engley (D/E) neutralizing broth andsubsequent quantitative plating on D/E agar. The Log10 reduction (LR) was determined by comparing the CFUs recovered from the segments
to the initial inoculum concentration as well as to the positive control. Each test was done in triplicate. Percent increase/decrease inbioburden (adherent microorganisms) was calculated from Log10 reduction results.
Results:
Arrowg+ard Blue Advance® PICC

Bard® PICC

Angiodynamics Bioflo® PICC

Challenge
Concentration(CFU/ml)

Recovered
Concentration(CFU/ml)

Percent
decrease/increase inbioburden(%)

Methicillin Resistant
Staphylococcus aureus
ATCC 33591

150,000

0100.00

150,000

2,398,833-1,499.22

150,000

3,235,937-2,057.29

Carbapenem ResistantEnterobacter cloacae
BAA-2468

150,000

0100.00

150,000

32,359,366-21,472.91

150,000

23,988,329-15,892.22

Carbapenem ResistantEscherichia coli BAA2469

150,000

0100.00

150,000

478,630-219.09

150,000

1,202,264-701.51

Carbapenem Resistant
Klebsiella pneumoniae
BAA-2470

150,000

0100.00

150,000

64,565,423-42,943.62

150,000

17,782,794-11,755.20

Methicillin Resistant
Staphylococcus
epidermidis ATCC 51625

150,000

0100.00

150,000

3,981

97.35

150,000

1,047

99.30

Vancomycin ResistantEnterococcus faecalis
ATCC 51299

150,000

0100.00

150,000

3,715,352-2,376.90

150,000

2,630,268-1,653.51

Organism

Challenge
Concentration(CFU/ml)

Recovered
Concentration(CFU/ml)

Percent
decrease/increase inbioburden(%)

Challenge
Concentration(CFU/ml)

Recovered
Concentration(CFU/ml)

Percent
decrease/increase inbioburden(%)

Disclosure Statement – Study was funded by and authors are employed by Teleflex LLC.

Rx only.
Contraindications: Clinical assessment of the patient must be completed to ensure no contraindications exist. Arrowg+ard Blue Advance®
Catheters are contraindicated in the following areas:• Patients with known hypersensitivity to chlorhexidine• In presence of device related infections• In presence of previous or current thrombosis in the intended vessel or along the catheterized vessel pathway.
No correlation between in vitro/in vivo testing methods and clinical outcomes have currently been ascertained.
References:
1. Centers for Disease Control and Prevention. (2019). Biggest Threats and Data: 2019 AR Threats Report. Retrieved from https://www.cdc.
gov/drugresistance/biggest-threats.html on 1/28/2020
2. In vitro data on file 2010: AVER-004371 and AVER-004483. No correlation between in vitro / in vivo testing methods and clinicaloutcomes have currently been ascertained.
3. Gupta N, Giare-Patel K, et al. Are PICCs with eluting technology more effective against antibiotic resistant bacteria than non-eluting
technology? Poster #T3. Disclosure Statement – Study was funded by and authors are employed by Teleflex LLC.

Bard is a trademark of C.R. Bard, Inc. BioFlo is a trademark of AngioDynamics, Inc.
Teleflex, the Teleflex logo, Arrow, and Arrowg+ard Blue Advance are trademarks or registered trademarks ofTeleflex Incorporated or its affiliates, in the U.S. and/or other countries. All other marks are the property of their respective owners.
© 2020 Teleflex Incorporated. All rights reserved. MC-006653 LA EN